AbbVie seeks Restasis follow-up with small option fee for Aldeyra’s eye drops, despite a potential 'imminent' CRL

As AbbVie’s sales of its dry eye disease drug Restasis continue to slide following the first generic approval in February 2022 …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ab­b­Vie seeks Resta­sis fol­low-up with small op­tion fee for Aldeyra’s eye drops, de­spite a po­ten­tial 'im­mi­nen­t' CRL